Alpha1-antitrypsin deficiency†

Managing Alpha1 begins
with understanding it

ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)] is a medicine made from human Alpha1-Proteinase Inhibitor (Alpha1-PI), which is also known as Alpha1-antitrypsin (AAT). It is used to treat adults with lung disease (emphysema) caused by severe Alpha1 antitrypsin (AAT) deficiency.

It is not known how increasing AAT levels with ARALAST NP or other Alpha1-PI products impacts worsening lung function or emphysema. The long-term effects of AAT with ARALAST NP have not been studied. ARALAST NP is not for use in lung disease other than severe Alpha1-PI deficiency.

†Alpha1-antitrypsin deficiency is sometimes referred to as Alpha1 or Alpha1 deficiency

Aralast 20-year anniversary sticker. Aralast product.

*Initial FDA approval: 2002

Understand inherited Alpha1 deficiency

Begin with an awareness of how Alpha1 deficiency can impact you and your family.

Human lung icon indicating severe variants associated with emphysema.

Alpha1 is a protein that helps protect the lungs.

The Alpha1 protein circulates in the bloodstream and works to protect the lungs from inflammation due to infection or inhaled irritants, such as tobacco smoke.

People with Alpha1 deficiency have low or absent levels of the protective Alpha1 protein.

Double helix DNA indicating Alpha1 deficiency is a hereditary disorder.

Alpha1 deficiency can run in families.

Alpha1 deficiency is an inherited disorder in which a genetic mutation impacts the body’s ability to produce sufficient levels of the Alpha1 protein.

A person who inherits two deficient Alpha1 genes—one from each parent—has Alpha1 deficiency.

Recycle drop icon indicating the cause of emphysema.

Emphysema may be caused by a severe Alpha1 deficiency in rare cases.

Without enough functional Alpha1, lung damage can develop, usually in people between 20 and 50 years of age.

A severe Alpha1 deficiency may lead to emphysema—a lung condition that causes shortness of breath—with symptoms that can worsen over time.

Family tree depicting inheritance of normal Alpha1 gene vs. deficient Alpha1 gene.

Inheritance of Alpha1 deficiency:

Everyone has two copies of the Alpha1 gene. If both parents have one deficient Alpha1 gene and one normal Alpha1 gene, there’s a 25% chance their child could have two deficient genes and Alpha1 deficiency, a 50% chance their child could carry one deficient gene, and a 25% chance their child would inherit two normal Alpha1 genes.

Know that you’re not alone

Information and support are available to help you move forward with treatment.

Three purple and one blue people icons indicating that about 1 of 3,000 to 5,000 people may have AAT deficiency.

About 1 of every 3,000 to 5,000 people in the U.S. may have Alpha1 deficiency.

Alpha1 deficiency is the most common known genetic cause of emphysema.

Chat bubble.

Talk to your doctor.

Your healthcare professional can help if you have questions about family testing, living with Alpha1 deficiency, or augmentation therapy.

Learn about augmentation therapy

The more you know, the more you’ll understand how important treatment can be.

Three arrows pointing up.

ARALAST NP increases the levels of the Alpha1 protein in your blood and lungs.

Augmentation therapy with ARALAST NP is typically given once a week to help replace the low or absent levels of the protein.

Healthcare professional icon.

Treatment is administered by a doctor or nurse as an intravenous (into a vein) infusion.

An infusion of ARALAST NP may take approximately 15 minutes, depending on body weight and infusion rate.*

You and your doctor can choose the infusion setting that is right for you.

Cross inside a circle indicating a clinic or physician's office.

In the clinic by a healthcare provider

Intravenous (IV) infusion icon representing outpatient infusion.

At an outpatient infusion center

House icon representing home infusion via a home health agency.

At home by a healthcare provider

*Infusion time is estimated, based on a 165-lb adult patient receiving the recommended dose at the maximum infusion rate, based on the product labeling.
Actual infusion time will vary from person to person.

Tailored support for you throughout your Alpha-1 augmentation therapy

After you and your physician choose a treatment path, Takeda Patient Support is here for you with a range of personalized services for your treatment journey.

We know living with Alpha-1 antitrypsin deficiency looks different for everyone. We get to know you, understand who you are, and learn what’s important to you—so we can help provide the support you need when it comes to your treatment.

Takeda Patient Support is a product support program for people who have been prescribed ARALAST NP. Our support specialists are here to address your questions and concerns and help get you the answers, resources, and tools you need.

Takeda Patient Support

Some of the ways we can assist include:

Enrolling you in the Takeda Patient Support Co-Pay Assistance Program, if you qualify*

Working with your specialty pharmacy (or site of care) to help you receive ARALAST NP

Navigating the health insurance process

Directing you to community support resources and education

Providing you with tips and timely information throughout your ARALAST NP treatment

*To be eligible, you must be enrolled in Takeda Patient Support and have commercial insurance. Other terms and conditions apply.
Call us for more details.

Person talking on the phone.

The Takeda Patient Support Co-Pay Assistance Program may help you save on your prescribed Takeda treatment.†

The program can cover up to 100% of your out-of-pocket co-pay costs, if you're eligible. To be eligible for this program, you must:

  1. Be prescribed a Takeda treatment for a condition that is approved by the Food and Drug Administration (FDA) to treat. This is called an "approved indication." Ask your healthcare provider if you're not sure.
  2. Have commercial insurance. This includes Health Insurance Marketplace plans.
    • Commercial insurance does not include Medicare, Medicaid, Veterans Affairs (VA), or other federal or state health plans.
  3. Be enrolled in Takeda Patient Support.

See below for terms and conditions.
If you can't afford your treatment, we may be able to connect you to programs that may help.

Not enrolled and want to get started? Here's what to do:

  1. Work with your healthcare provider to complete the Start Form for your prescribed Alpha-1 therapy
  2. Sign the Patient Authorization section of the Start Form
  3. Takeda Patient Support will confirm your eligibility
  4. Your dedicated support specialist will contact you

If English is not your preferred language, let your Takeda Patient Support specialist know. The team can communicate with you over the phone in a variety of languages-using a translation service.

VISIT TAKEDA PATIENT SUPPORT

Already enrolled and want to connect?

Our support specialists are never more than a tap or call away—1-866-888-0660, Monday through Friday, 8:30 AM to 8:00 PM ET.

†IMPORTANT NOTICE: Takeda's Co-pay Assistance Program ("the Program") provides financial support for commercially insured patients who qualify for the Program. Participation in the Program and provision of financial support is subject to all Program terms and conditions, including but not limited to eligibility requirements, the Program maximum benefit per claim and the annual calendar year Program maximum ("Annual Program Maximum"). The Annual Program Maximum for your prescribed Takeda product can be found by visiting: www.takedapatientsupport.com/copay.

By enrolling in the Program, you agree that the Program is intended solely for the benefit of you—not health plans and/or their partners. Further, you agree to comply with all applicable requirements of your health plan. The Program cannot be used if the patient is a beneficiary of, or any part of the prescription is covered by: 1) any federal, state, or government-funded healthcare program (Medicare, Medicare Advantage, Medicaid, TRICARE, etc.), including a state pharmaceutical assistance program (the Federal Employees Health Benefit (FEHB) Program is not a government-funded healthcare program for the purpose of this offer), 2) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, or 3) insurance that is paying the entire cost of the prescription. No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third-party payer, whether public or private.

Some health plans have established programs referred to as ‘co-pay maximizer' programs. A co-pay maximizer program is one in which the amount of a patient's out-of-pocket costs is adjusted to reflect the availability of support offered by a manufacturer's co-pay assistance program. If you are enrolled in a co-pay maximizer program, your Annual Program Maximum may vary over time to ensure the program funds are used for your benefit (for the benefit of the patient). Takeda also reserves the right to reduce or eliminate the co-pay assistance available to patients enrolled in an insurance plan that utilizes a co-pay maximizer program.

If you learn your health plan has implemented a co-pay maximizer program, you agree to notify the Program immediately by calling 1-866-888-0660. It may be possible that you are unaware whether you are subject to a co-pay maximizer program when you enroll or re-enroll in the Program. Takeda will monitor program utilization data and reserves the right to discontinue assistance under the Program at any time if Takeda determines that you are subject to a co-pay maximizer, or similar program.

The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law.

This Program offer is not transferable and is limited to one offer per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, co-pay maximizer, alternative funding program, co-pay accumulator, or other offer, including those from third parties and companies that help insurers or health plan manage costs. Not valid if reproduced.

By utilizing the Program, you hereby accept and agree to abide by these terms and conditions. Any individual or entity who enrolls or assists in the enrollment of a patient in the Program represents that the patient meets the eligibility criteria and other requirements described herein. You must meet the Program eligibility requirements every time you use the Program. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice, and other terms and conditions may apply.